The Armour Thyroid dose should be increased immediately
This patient is clinically and biochemically undertreated—the TSH rising from 3.3 to 8.5 mIU/L with worsening fatigue clearly indicates inadequate thyroid hormone replacement. The 60 mg Armour Thyroid dose is insufficient to replace the 112 mcg of levothyroxine she was previously taking.
Why This Happened: Dose Conversion Error
The switch was made using an incorrect conversion ratio. Standard conversion from levothyroxine to desiccated thyroid extract (DTE) is approximately 100 mcg levothyroxine = 60-65 mg DTE 1. Your patient was on 112 mcg Synthroid, which should have been converted to approximately 65-75 mg Armour Thyroid, not 60 mg. This explains the biochemical hypothyroidism.
The Clinical Picture Confirms Underdosing
- TSH 8.5 mIU/L: This is overtly elevated and indicates primary hypothyroidism requiring dose adjustment 1
- Increased fatigue: Classic symptom of inadequate thyroid replacement 1
- 4 lb weight loss: Paradoxical but can occur with medication changes; not a reliable indicator of adequate dosing
- Improved brain fog: This isolated improvement does NOT justify accepting an elevated TSH—it may be placebo effect or unrelated to the medication change
Specific Dosing Recommendation
Increase the Armour Thyroid to 75-90 mg daily (starting at 75 mg is reasonable). The guidelines indicate that for TSH 8-12 mIU/L, dose adjustments of 12.5-25 mcg levothyroxine equivalent are appropriate 1. Since 15 mg DTE ≈ 25 mcg levothyroxine, increasing by 15-30 mg DTE is appropriate.
Monitoring Plan
- Recheck TSH in 6-8 weeks after dose adjustment 1
- Target TSH should be in the normal range (0.4-4.0 mIU/L), ideally between 0.5-2.5 mIU/L for most patients 1
- Continue adjusting in 15 mg increments until TSH normalizes
Critical Pitfall to Avoid
Do not be misled by the single symptom improvement (brain fog) while ignoring objective biochemical evidence of hypothyroidism and worsening fatigue. The FDA labeling for levothyroxine products explicitly states that "persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose" requires investigation and adjustment 2. In this case, the dose is clearly inadequate.
Important Context About Desiccated Thyroid
While the AACE/ATA guidelines state there is "no evidence to support using desiccated thyroid hormone in preference to L-thyroxine monotherapy" 1, and DTE "has not been systematically studied" 1, recent research shows that some patients do report symptomatic benefit from DTE 3, 4, 5. However, this benefit only occurs when the TSH is normalized—not when the patient remains biochemically hypothyroid as in your case.
The T4:T3 ratio in Armour Thyroid is approximately 4:1 by weight 1, which provides more T3 than levothyroxine monotherapy. This may explain why some patients prefer it 4, 5, but again, only when properly dosed to achieve euthyroidism.
Bottom Line
This is not a "typical reaction"—this is straightforward underdosing from an inadequate conversion. The elevated TSH and increased fatigue mandate dose escalation. The improved brain fog is insufficient justification to accept biochemical hypothyroidism, which carries long-term risks including cardiovascular complications, hyperlipidemia, and reduced quality of life 1.